Angiopoietin-like protein 2(ANGPTL2)stimulates inflammation and is important in the pathogenesis of diabetic kidney disease(DKD).Irbesartan is helpful in reducing diabetes-induced renal damage.In this study,the effect...Angiopoietin-like protein 2(ANGPTL2)stimulates inflammation and is important in the pathogenesis of diabetic kidney disease(DKD).Irbesartan is helpful in reducing diabetes-induced renal damage.In this study,the effects of irbesartan on DKD and its renal protective role involving ANGPTL2 in DKD rats were examined.Wistar rats were divided into normal,DKD,and DKD+irbesartan groups.The DKD+irbesartan group was treated once daily for 8 weeks with 50 mg/kg irbesartan via intragastric gavage.The 24-h urinary albumin was determined each week,renal pathological changes were observed,and expression of ANGPTL2 and nuclear factor-kappa B(NF-κB)in rat renal tissue was assessed by immunohistochemistry.Mouse podocytes cultured in a high concentration of glucose were classified into four groups based on the irbesartan concentrations(0,25,50,and 75ºg/mL).Expression of ANGPTL2 and phosphorylated IκB-αwas assessed by Western blotting.The mRNA levels of ANGPTL2 and monocyte chemotactic protein 1(MCP-1)were assessed by real-time polymerase chain reaction.The DKD rats displayed proteinuria,podocyte injury,and increased ANGPTL2 and NF-κB expression.All were relieved by irbesartan treatment.In podocytes cultured in elevated glucose,ANGPTL2 and phosphorylated IκB-αwere overexpressed at the protein level,and ANGPTL2 and MCP-1 were highly expressed at the mRNA level.Irbesartan down-regulated ANGPTL2 and phosphorylated IκB-αexpression at the protein level and inhibited ANGPTL2 and MCP-1 expression at the mRNA level.The ameliorative effects of irbesartan against DKD involves podocyte protection and suppression of ANGPTL2.展开更多
目的:观察具有益气养阴活血作用的丹蛭降糖胶囊(DJC)对糖尿病合并高血压患者血清心房钠尿肽(ANP)、血管生成素样蛋白2(Angptl2)、血浆纤溶酶原激活物抑制剂-1(PAI-1)水平的影响。方法:纳入84例2型糖尿病合并高血压患者,随机分为治疗组4...目的:观察具有益气养阴活血作用的丹蛭降糖胶囊(DJC)对糖尿病合并高血压患者血清心房钠尿肽(ANP)、血管生成素样蛋白2(Angptl2)、血浆纤溶酶原激活物抑制剂-1(PAI-1)水平的影响。方法:纳入84例2型糖尿病合并高血压患者,随机分为治疗组42例和对照组42例。对照组患者予常规降压、降糖西药治疗,治疗组患者在常规西药治疗基础上加服丹蛭降糖胶囊,治疗周期均为12周。比较两组患者的中医症状积分及中医证候疗效,监测患者的SBP、DBP水平,检测患者的FPG、2 h PG、HbAlc及ANP、Angptl2、PAI-1水平。结果:(1)治疗后,对照组的中医证候疗效总有效率为75.61%,治疗组为92.50%,治疗组疗效优于对照组(P<0.01)。(2)治疗后,治疗组患者的倦怠乏力、头痛眩晕、五心烦热、腰膝酸软、耳鸣心悸症状积分均下降(P<0.05,P<0.01),对照组患者仅耳鸣心悸症状积分下降(P<0.05),且治疗组患者的头痛眩晕、五心烦热、腰膝酸软、耳鸣心悸症状积分低于对照组(P<0.05,P<0.01)。(3)治疗后,两组患者的血清ANP、Angptl2、PAI-1水平较治疗前均明显降低(P<0.01),且治疗组患者的血清ANP、Angptl2、PAI-1水平均低于对照组(P<0.01,P<0.05)。(4)治疗后,两组患者的SBP、DBP、FPG、2h PG及HbAlc水平较治疗前均明显降低(P<0.01),且治疗组患者的DBP、FPG水平低于对照组(P<0.05)。结论:具有益气养阴活血作用的丹蛭降糖胶囊结合常规西药较单纯采用常规西药能够更好地改善2型糖尿病合并高血压患者的临床症状,调节血压、血糖,其作用机制可能与下调ANP、Angptl2、PAI-1的高表达相关。展开更多
基金This study was supported by Jiangsu University Medical Clinical Science and Technology Development(No.JLY201220045).
文摘Angiopoietin-like protein 2(ANGPTL2)stimulates inflammation and is important in the pathogenesis of diabetic kidney disease(DKD).Irbesartan is helpful in reducing diabetes-induced renal damage.In this study,the effects of irbesartan on DKD and its renal protective role involving ANGPTL2 in DKD rats were examined.Wistar rats were divided into normal,DKD,and DKD+irbesartan groups.The DKD+irbesartan group was treated once daily for 8 weeks with 50 mg/kg irbesartan via intragastric gavage.The 24-h urinary albumin was determined each week,renal pathological changes were observed,and expression of ANGPTL2 and nuclear factor-kappa B(NF-κB)in rat renal tissue was assessed by immunohistochemistry.Mouse podocytes cultured in a high concentration of glucose were classified into four groups based on the irbesartan concentrations(0,25,50,and 75ºg/mL).Expression of ANGPTL2 and phosphorylated IκB-αwas assessed by Western blotting.The mRNA levels of ANGPTL2 and monocyte chemotactic protein 1(MCP-1)were assessed by real-time polymerase chain reaction.The DKD rats displayed proteinuria,podocyte injury,and increased ANGPTL2 and NF-κB expression.All were relieved by irbesartan treatment.In podocytes cultured in elevated glucose,ANGPTL2 and phosphorylated IκB-αwere overexpressed at the protein level,and ANGPTL2 and MCP-1 were highly expressed at the mRNA level.Irbesartan down-regulated ANGPTL2 and phosphorylated IκB-αexpression at the protein level and inhibited ANGPTL2 and MCP-1 expression at the mRNA level.The ameliorative effects of irbesartan against DKD involves podocyte protection and suppression of ANGPTL2.
文摘目的:观察具有益气养阴活血作用的丹蛭降糖胶囊(DJC)对糖尿病合并高血压患者血清心房钠尿肽(ANP)、血管生成素样蛋白2(Angptl2)、血浆纤溶酶原激活物抑制剂-1(PAI-1)水平的影响。方法:纳入84例2型糖尿病合并高血压患者,随机分为治疗组42例和对照组42例。对照组患者予常规降压、降糖西药治疗,治疗组患者在常规西药治疗基础上加服丹蛭降糖胶囊,治疗周期均为12周。比较两组患者的中医症状积分及中医证候疗效,监测患者的SBP、DBP水平,检测患者的FPG、2 h PG、HbAlc及ANP、Angptl2、PAI-1水平。结果:(1)治疗后,对照组的中医证候疗效总有效率为75.61%,治疗组为92.50%,治疗组疗效优于对照组(P<0.01)。(2)治疗后,治疗组患者的倦怠乏力、头痛眩晕、五心烦热、腰膝酸软、耳鸣心悸症状积分均下降(P<0.05,P<0.01),对照组患者仅耳鸣心悸症状积分下降(P<0.05),且治疗组患者的头痛眩晕、五心烦热、腰膝酸软、耳鸣心悸症状积分低于对照组(P<0.05,P<0.01)。(3)治疗后,两组患者的血清ANP、Angptl2、PAI-1水平较治疗前均明显降低(P<0.01),且治疗组患者的血清ANP、Angptl2、PAI-1水平均低于对照组(P<0.01,P<0.05)。(4)治疗后,两组患者的SBP、DBP、FPG、2h PG及HbAlc水平较治疗前均明显降低(P<0.01),且治疗组患者的DBP、FPG水平低于对照组(P<0.05)。结论:具有益气养阴活血作用的丹蛭降糖胶囊结合常规西药较单纯采用常规西药能够更好地改善2型糖尿病合并高血压患者的临床症状,调节血压、血糖,其作用机制可能与下调ANP、Angptl2、PAI-1的高表达相关。
